Travere Therapeutics, Inc. Common Stock
$63.39
-$1.35 (-2.09%)
$62.47Day Range$64.89
Key Statistics
Market Cap
$6.10B
Shares Outstanding
94.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 23, 2003
Round Lot
100
Locale
US
Trading Data
Day Open
$64.89
Day High
$64.89
Day Low
$62.47
Volume
534.7K
VWAP
$63.65
Prev Close
$64.74
Transactions
--
Acc. Volume
--
About Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
PHARMACEUTICAL PREPARATIONSSIC 2834497 employees3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130888-969-7879IPO Jul 23, 2003US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001438533
- Composite FIGI
- BBG000P9D6W9
- Share Class FIGI
- BBG001SL72C5
- Ticker Root
- TVTX
- SIC Code
- 2834
About Travere Therapeutics, Inc. Common Stock (TVTX) Stock
Travere Therapeutics, Inc. Common Stock (TVTX) closed the 2026-09-18 session at $63.38, down 2.09% versus the previous close (-1.35). The stock opened at $64.89 and traded between $62.47 and $64.89 during that session. Session trading volume was 535K shares. The volume-weighted average price (VWAP) is $63.65.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics, Inc. Common Stock has a market capitalization of $6.10 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TVTX is listed on the XNAS exchange. The company employs approximately 497 people. Travere Therapeutics, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2003-07-23.
On this page you can find market TVTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.